Pfizer Starts Phase 3 Study of MRNA-Based Flu Vaccine
September 14 2022 - 7:26AM
Dow Jones News
By Will Feuer
Pfizer Inc. said it has dosed the first participants in its new
Phase 3 study to evaluate its modified RNA vaccine candidate for
influenza.
The late-stage study will test the shot's efficacy, safety,
tolerability and immunogenicity in about 25,000 healthy U.S.
adults, Pfizer said.
"For years, there has been a need to better address the burden
of influenza, despite the use of existing seasonal flu vaccines,"
said Annaliesa Anderson, chief scientific officer of vaccine
research and development for Pfizer.
Pfizer said the flexibility of mRNA technology and its rapid
manufacturing could allow better influenza vaccine strain matches
in future years. Influenza causes 140,000 to 710,000
hospitalizations, 12,000 to 52,000 deaths and about $25 billion in
economic loss in the U.S. annually, Pfizer said.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
September 14, 2022 07:11 ET (11:11 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024